EGFR and cancer: In addition, B-ASO may have a dual effect: on the one hand, they provide a therapeutic platform for BNCT, and on the other hand, they reduce the mRNA of EGFR by antisense activity, thus decreasing the radio-resistance of cancer cells [49,50,51].